Eris Lifesciences Q1 Results FY26: Q1 PAT Rises 41.63% to ₹117.99 Crore; Revenue Up 7.40% YoY

Eris Lifesciences Q1 Results FY26: Eris Lifesciences posted its Q1 results on 5th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹117.99 crores against revenue of ₹773.00 crores. During Q1 FY26, the profit increase of the company was recorded at 41.63% YoY, and the revenue increase for the same period was 7.40%. 

Eris Lifesciences Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Eris Lifesciences Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Eris Lifesciences Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Eris Lifesciences clocked Q1 FY26 consolidated revenue of ₹773.00 crores vs ₹719.72 crores. 
• On the profit front, Eris Lifesciences earned a consolidated PAT of ₹117.99 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹83.311 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 41.63% YoY, and revenue rose 7.40% YoY. 
• As per the standalone figures, the quarterly PAT of Eris Lifesciences has increased by 486.80% and revenue has increased by 26.70% YoY.

Eris Lifesciences Share Price Performance

On the opening bell of 5th August 2025, the shares of Eris Lifesciences opened at ₹1812.00 per share. However, the initial gains are wiped out as of now, and Eris Lifesciences shares are trading at ₹1804.10 per share, lower than their opening price. 

Considering the long-term performance, Eris Lifesciences shares have yielded close to 67.22% returns in the past 1 year, and 5-year returns stand at 236.09%. Over the maximum timeframe, the Eris Lifesciences share provided 15,725.44% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Eris Lifesciences shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Canara Bank Q1 Results FY26: Q1 PAT Fall 21.45 to ₹3,194.95 crore; Revenue Surged 12.11% YoY

Recent Articles

Marico Q1 Results FY26: Q1 PAT Up 8.62% to ₹504.00 Crore; Revenue Surged 23.31% YoY

Tata Investment Corporation Q1 Results FY26: Q1 PAT Soars 11.62% to ₹146.30 Crore; Revenue Surged 2.11% YoY

Shree Cement Q1 Results FY26: Q1 PAT Surges 130.67% to ₹642.66 Crore; Revenue Surged 3.06% YoY

Escorts Kubota Q1 Results FY26: Q1 PAT Jumps 363.16% to ₹1,397.11 Crore; Revenue Down 2.86% YoY

Knowledge Realty Trust REIT IPO GMP & Review: Apply or Avoid?

BLT Logistics IPO GMP & Review: Apply or Avoid?

RR Kabel Q1 Results FY26: Q1 PAT Jumps 39.44% to ₹89.77 Crore; Revenue Surged 13.85% YoY

Kirlosker Brothers Q1 Results FY26: Q1 PAT Soars 2.46% to ₹66.70 Crore; Revenue Declined 5.03% YoY

Aaradhya Disposal IPO GMP & Review: Apply or Avoid?

Aarti Industries Q1 Results FY26: Q1 PAT Down 68.61% to ₹43.00 Crore; Revenue Declined 9.45% YoY